pSivida Corp. (PSDV) saw its loss widen to $5.14 million, or $0.15 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $5.04 million, or $0.15 a share.

Revenue during the quarter surged 82.10 percent to $0.59 million from $0.32 million in the previous year period.

Operating loss for the quarter was $5.16 million, compared with an operating loss of $5.10 million in the previous year period.

"We continue to make substantial regulatory, clinical and collaborative progress with our Durasert technology," commented Nancy Lurker, president and chief executive officer. "Our near-term goals remain: 1) unmask our second pivotal Phase 3 clinical trial for Durasert three-year uveitis and file regulatory approval applications in both the EU and US in calendar 2017, 2) establish additional collaboration partnerships for our proven Durasert technology, and 3) finalize an EU out-license partner for our three-year uveitis product candidate. Our efforts to date are yielding promising results and the successful achievement of these upcoming milestones will demonstrate the potential of our moderate risk/nearer term product development programs."